Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 IL-17 contributes to the development of chronic rejection in a murine heart transplant model.

Literature DB >> 20130970

IL-17 contributes to the development of chronic rejection in a murine heart transplant model.

Satoshi Itoh¹, Susumu Nakae, Robert C Axtell, Jeffrey B Velotta, Naoyuki Kimura, Naoki Kajiwara, Yoichiro Iwakura, Hirohisa Saito, Hideo Adachi, Lawrence Steinman, Robert C Robbins, Michael P Fischbein.

Abstract

BACKGROUND: Although interleukin-17 (IL-17) has been reported to participate in the pathogenesis of infectious, autoimmune and allergic disorders, the precise role in allograft rejection remains uncertain. This study illustrates that IL-17 contributes to the pathogenesis of chronic allograft rejection. RESULT: Utilizing a murine heterotopic heart transplant model system, IL-17-deficient recipient mice had decreased allograft inflammatory cell recruitment, decreased IL-6, MCP-1, and KC production, and reduced graft coronary artery disease (GCAD). Intragraft gamma delta (gammadelta) T cells appear to be the predominant source of IL-17 production.
CONCLUSION: Therefore, IL-17 neutralization may provide a potential target for novel therapeutic treatment for cardiac allograft rejection.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20130970 DOI： 10.1007/s10875-009-9366-9

Source DB: PubMed Journal: J Clin Immunol ISSN： 0271-9142 Impact factor: 8.317

32 in total

1. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes.

Authors: G Tellides; D A Tereb; N C Kirkiles-Smith; R W Kim; J H Wilson; J S Schechner; M I Lorber; J S Pober
Journal: Nature Date: 2000-01-13 Impact factor: 49.962

2. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts.

Authors: H Nagano; R N Mitchell; M K Taylor; S Hasegawa; N L Tilney; P Libby
Journal: J Clin Invest Date: 1997-08-01 Impact factor: 14.808

3. Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells.

Authors: R N Salomon; C C Hughes; F J Schoen; D D Payne; J S Pober; P Libby
Journal: Am J Pathol Date: 1991-04 Impact factor: 4.307

4. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

Authors: Mandy J McGeachy; Kristian S Bak-Jensen; Yi Chen; Cristina M Tato; Wendy Blumenschein; Terrill McClanahan; Daniel J Cua
Journal: Nat Immunol Date: 2007-11-11 Impact factor: 25.606

5. Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma.

Authors: Kirk D C Jensen; Xiaoqin Su; Sunny Shin; Luke Li; Sawsan Youssef; Sho Yamasaki; Lawrence Steinman; Takashi Saito; Richard M Locksley; Mark M Davis; Nicole Baumgarth; Yueh-hsiu Chien
Journal: Immunity Date: 2008-06-26 Impact factor: 31.745

6. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors.

Authors: M A Antonysamy; W C Fanslow; F Fu; W Li; S Qian; A B Troutt; A W Thomson
Journal: J Immunol Date: 1999-01-01 Impact factor: 5.422

7. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities.

Authors: Erika A Rickel; Lori A Siegel; Bo-Rin Park Yoon; James B Rottman; David G Kugler; David A Swart; Penny M Anders; Joel E Tocker; Michael R Comeau; Alison L Budelsky
Journal: J Immunol Date: 2008-09-15 Impact factor: 5.422

8. Aging augments IL-17 T-cell alloimmune responses.

Authors: B M Tesar; W Du; A C Shirali; W E Walker; H Shen; D R Goldstein
Journal: Am J Transplant Date: 2008-10-31 Impact factor: 8.086

9. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Authors: Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger
Journal: Immunity Date: 2006-02 Impact factor: 31.745

IL-17 contributes to the development of chronic rejection in a murine heart transplant model.

1. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes.

2. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts.

3. Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells.

4. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

5. Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma.

6. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors.

7. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities.

8. Aging augments IL-17 T-cell alloimmune responses.

9. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

10. Gene transfer of soluble interleukin-17 receptor prolongs cardiac allograft survival in a rat model.

Review 1. Role of Th17 cells and IL-17 in lung transplant rejection.

Review 2. Interleukin 17 in vascular inflammation.

3. Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury.

4. Tim-1-Fc suppresses chronic cardiac allograft rejection and vasculopathy by reducing IL-17 production.

Review 5. Impact of hyperlipidemia on alloimmunity.

Review 6. Significance of T helper 17 immunity in transplantation.

7. Hyperlipidemia Promotes Anti-Donor Th17 Responses That Accelerate Allograft Rejection.

8. Interleukin-17 plays a critical role in the acute rejection of intestinal transplantation.

9. Anti-IL-17 therapy restricts and reverses late-term corneal allorejection.

10. SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection.